Retroperitoneal germ cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration

Por Womeldorph, Craig M, Zalupski, Mark M, Knoepp, Stewart M, Soltani, Mohammad, Elmunzer, B Joseph
Publicado em 2010

Using (18)F Fluorodeoxyglucose Positron Emission Tomography (FDG PET) to Monitor Clinical Outcomes in Patients Treated with Neoadjuvant Chemo-Radiotherapy for Locally Advanced Panc...

Por Choi, Minsig, Heilbrun, Lance K., Venkatramanamoorthy, Raghu, Lawhorn-Crews, Jawana M., Zalupski, Mark M., Shields, Anthony F.
Publicado em 2010

A phase II study of biweekly cisplatin, fixed dose rate gemcitabine and infusional 5-fluorouracil in patients with metastatic pancreatic and biliary cancers

Por Davis, Elizabeth J., Griffith, Kent A., Kim, Edward J., Ruch, Joshua M., McDonnell, Kevin J., Zalupski, Mark M.
Publicado no Am J Clin Oncol (2018)

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy

Por HAMMAD, Nazik, HEILBRUN, Lance K, PHILIP, Philip A, SHIELDS, Anthony F, ZALUPSKI, Mark M, VENKATRAMANAMOORTHY, Raghu, EL-RAYES, Bassel F
Publicado em 2010

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

Por Gartner, Elaina M., Griffith, Kent A., Pan, Quintin, Brewer, George J., Henja, Gwen F., Merajver, Sofia D., Zalupski, Mark M.
Publicado em 2008

DEPTOR has growth suppression activity against pancreatic cancer cells

Por Li, Hua, Sun, Grace Y., Zhao, Yongchao, Thomas, Dafydd, Greenson, Joel K., Zalupski, Mark M., Ben-Josef, Edgar, Sun, Yi
Publicado no Oncotarget (2014)

Neoadjuvant Stereotactic Body Radiation Therapy (SBRT), Capecitabine, and Liver Transplantation for Unresectable Hilar Cholangiocarcinoma

Por Welling, Theodore H., Feng, Mary, Wan, Shanshan, Hwang, Sin Ye, Volk, Michael L., Lawrence, Theodore S., Zalupski, Mark M., Sonnenday, Christopher J.
Publicado em 2013

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

Por Davis, Elizabeth J., Zhao, Lili, Lucas, David R., Schuetze, Scott M., Baker, Laurence H., Zalupski, Mark M., Thomas, Dafydd, Chugh, Rashmi
Publicado no BMC Cancer (2016)

Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concur...

Por Vainshtein, Jeffrey M., Schipper, Matthew, Zalupski, Mark M., Lawrence, Theodore S., Abrams, Ross, Francis, Isaac R., Khan, Gazala, Leslie, William, Ben-Josef, Edgar
Publicado em 2012

Carbohydrate Antigen 19-9 Is a Prognostic and Predictive Biomarker in Patients With Advanced Pancreatic Cancer Who Receive Gemcitabine-Containing Chemotherapy: A Pooled Analysis of...

Por Bauer, Todd M., El-Rayes, Bassel F., Li, Xiaobai, Hammad, Nazik, Philip, Philip A., Shields, Anthony F., Zalupski, Mark M., Bekaii-Saab, Tanios
Publicado no Cancer (2012)

Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy

Por Cuneo, Kyle C., Morgan, Meredith A., Griffith, Kent A., Hawkins, Peter G., Greenson, Joel K., Ben-Josef, Edgar, Lawrence, Theodore S., Zalupski, Mark M.
Publicado no Int J Radiat Oncol Biol Phys (2017)

Original Article A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

Por Cohen, Steven J., Zalupski, Mark M., Modiano, Manuel R., Conkling, Paul, Patt, Yehuda Z., Davis, Peg, Dorr, Robert T., Boytim, Michelle L., Hersh, Evan M.
Publicado em 2009

A Phase I Trial of Cabozantinib and Gemcitabine in Advanced Pancreatic Cancer

Por Zhen, David B, Griffith, Kent A, Ruch, Joshua M, Camphausen, Kevin, Savage, Jason E, Kim, Edward J, Sahai, Vaibhav, Simeone, Diane M, Zalupski, Mark M
Publicado no Invest New Drugs (2016)

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial

Por Sahai, Vaibhav, Catalano, Paul J., Zalupski, Mark M., Lubner, Sam Joseph, Menge, Mark R., Nimeiri, Halla Sayed, Munshi, Hidayatullah G., Benson, Al Bowen, O’Dwyer, Peter J.
Publicado no JAMA Oncol (2018)

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer

Por El-Rayes, Bassel F., Zalupski, Mark M., Manza, Stephanie G., Rusin, Barbara, Ferris, Ann Marie, Vaishampayan, Ulka, Heilbrun, Lance K., Venkatramanamoorthy, Raghu, Shields, Anthony F., Philip, Philip A.
Publicado em 2007

Quality of life in a prospective multi-center phase II trial of neoadjuvant full dose gemcitabine, oxaliplatin and radiation in patients with resectable or borderline resectable pa...

Por Serrano, Pablo E., Herman, Joseph M., Griffith, Kent A., Zalupski, Mark M, Kim, Edward J., Bekaii-Saab, Tanios S., Ben-Josef, Edgar, Dawson, Laura A., Ringash, Jolie, Wei, Alice C.
Publicado no Int J Radiat Oncol Biol Phys (2014)

Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Canc...

Por Tran, Nguyen H., Sahai, Vaibhav, Griffith, Kent A., Nathan, Hari, Kaza, Ravi, Cuneo, Kyle C., Shi, Jiaqi, Kim, Edward, Sonnenday, Christopher J., Cho, Clifford S., Lawrence, Theodore S., Zalupski, Mark M.
Publicado no Int J Radiat Oncol Biol Phys (2019)

A phase I/II trial of intensity-modulated radiation (IMRT) dose escalation with concurrent fixed- dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer

Por Ben-Josef, Edgar, Schipper, Mathew, Francis, Isaac R, Hadley, Scott, Ten-Haken, Randall, Lawrence, Theodore, Normolle, Daniel, Simeone, Diane M., Sonnenday, Christopher, Abrams, Ross, Leslie, William, Khan, Gazala, Zalupski, Mark M.
Publicado em 2012

The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Por Herman, Joseph M., Narang, Amol K., Griffith, Kent A., Zalupski, Mark M., Reese, Jennifer B., Gearhart, Susan L., Azad, Nolifer S., Chan, June, Olsen, Leah, Efron, Jonathan E., Lawrence, Theodore S., Ben-Josef, Edgar
Publicado em 2012

Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Por Kim, Edward J., Sahai, Vaibhav, Abel, Ethan V., Griffith, Kent A., Greenson, Joel K., Takebe, Naoko, Khan, Gazala N., Blau, John L., Craig, Ronald, Balis, Ulysses G., Zalupski, Mark M., Simeone, Diane M.
Publicado no Clin Cancer Res (2014)